A Clinical Trial in Healthy Volunteers and Volunteers With Recurrent Genital Herpes to Study the Safety, Tolerability, and Immune Responses After Vaccination With an Investigational Vaccine Designed to Prevent Genital Herpes Lesions

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

318

Participants

Timeline

Start Date

December 8, 2022

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2026

Conditions
Genital Herpes Simplex Type 2
Interventions
BIOLOGICAL

BNT163

Anti-viral ribonucleic acid (RNA) vaccine for active immunization against HSV-2 administered as intramuscular injection

OTHER

Placebo

Placebo

Trial Locations (6)

19104

Hospital of the University of Pennsylvania, Philadelphia

27609

Accellacare Raleigh Medical Group, Raleigh

28401

Accellacare PMG Research Wilmington LLC, Wilmington

45212

CTI Clinical Research Center, Cincinnati

60640

Great Lakes Clinical Trials - Flourish Research, Chicago

85281

Alliance for Multispecialty Research, LLC, Tempe

Sponsors

Lead Sponsor

All Listed Sponsors
lead

BioNTech SE

INDUSTRY